Company news
Abeona Therapeutics Inc. news in 2019
Abeona Therapeutics Inc.'s news releases, calls and decks from 2019, newest first.
Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 23, 2019
Abeona Therapeutics Receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA
December 19, 2019
Abeona Announces Pricing of Public Offering of Common Stock and Pre‑Funded Warrants
December 19, 2019
Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants
December 18, 2019
Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
December 8, 2019
Abeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates
November 11, 2019
Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress
October 20, 2019
Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
October 14, 2019
Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa
September 22, 2019
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
April 3, 2019
Decks in 2019
- Investor Presentation (August 2019)
Investor deck · 38 slides · Aug 14, 2019